Compare APLD & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APLD | GKOS |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.0B |
| IPO Year | 2021 | 2015 |
| Metric | APLD | GKOS |
|---|---|---|
| Price | $31.55 | $126.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | $37.75 | ★ $126.92 |
| AVG Volume (30 Days) | ★ 18.9M | 643.7K |
| Earning Date | 04-08-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.45 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $144,193,000.00 | ★ $507,442,000.00 |
| Revenue This Year | $163.85 | $23.32 |
| Revenue Next Year | $64.81 | $27.43 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $3.81 | $73.16 |
| 52 Week High | $42.27 | $130.23 |
| Indicator | APLD | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 59.79 | 68.15 |
| Support Level | $28.40 | $81.54 |
| Resistance Level | $40.49 | $130.23 |
| Average True Range (ATR) | 2.20 | 4.37 |
| MACD | 0.89 | 1.45 |
| Stochastic Oscillator | 95.39 | 94.43 |
Applied Digital Corp is a designer, developer, and operator of next-generation digital infrastructure across North America. It provides digital infrastructure solutions and cloud services to industries like High-Performance Computing (HPC) and Artificial Intelligence (AI). The company operates in the following business segments: Data Center Hosting Business and HPC Hosting Business. The majority of its revenue is generated from the Data Center Hosting Business, which operates data centers to provide energized space to crypto mining customers.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.